Table 2.
Mesenchymal derived cell populations characterization in the adipose tissue graft groups.
| Cell Population Characterization | Lipoaspirate (A) (cells/mL) * | SVFs Isolation (B) (cells/mL) * | SVFs Enhanced Graft (Lipoaspirate + SVFs) (C) (cells/mL) * | Lipoaspirate Centrifuged (D) (cells/mL) * |
|---|---|---|---|---|
| Total cells | 65,800 | 13,625,000 | 427,650 | 207,750 |
| CD 34+ | 2829 | 7,766,250 | 277,970 | 149,580 |
| CD 45+ | 1974 | 258,8750 | 85,530 | 60,247 |
| CD 105+ | 0 | 40,8750 | 21,382 | 14,542 |
| CD 34+ CD 45+ | 329 | 1,635,000 | 59,870 | 39,472 |
| CD 105+ CD 45+ | 0 | 136,250 | 12,830 | 8310 |
| CD 105+ CD34+ | 0 | 408,750 | 17,106 | 14,542 |
| CD 90+ | 2632 | 7,221,250 | 273,696 | 124,650 |
| CD 31+ | 1316 | 3,133,750 | 85,530 | 51,937 |
| CD 31+ CD 45+ | 5922 | 953,750 | 38,488 | 33,240 |
| Total CD 34+, CD 45-, CD 105+ | 2500 | 5,722,500 | 200,995 | 110,107 |
* Values were reported as an average number of every analyzed samples in each group (A). Pure fat harvest lipoaspirate from all patients before any fat managing (CG2); (B). Stromal Vascular Fraction cells (SVFs) suspension sample (alone) from fat graft of five study group (SG) patients underwent Celution® system treatment; (C). SVFs-enhanced fat graft sample from five SG patients before injection; (D). Sample of standard centrifuged fat graft, according to Coleman’s technique, from five CG1 patients.